Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Velcicky J, Janser P, Gommermann N, Brenneisen S, Ilic S, Vangrevelinghe E, Stiefl N, Boettcher A, Arnold C, Malinverni C, Dawson J, Murgasova R, Desrayaud S, Beltz K, Hinniger A, Dekker C, Farady CJ, Mackay A. Velcicky J, et al. Among authors: stiefl n. J Med Chem. 2024 Jan 25;67(2):1544-1562. doi: 10.1021/acs.jmedchem.3c02098. Epub 2024 Jan 4. J Med Chem. 2024. PMID: 38175811
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
Kallen J, Bergsdorf C, Arnaud B, Bernhard M, Brichet M, Cobos-Correa A, Elhajouji A, Freuler F, Galimberti I, Guibourdenche C, Haenni S, Holzinger S, Hunziker J, Izaac A, Kaufmann M, Leder L, Martus HJ, von Matt P, Polyakov V, Roethlisberger P, Roma G, Stiefl N, Uteng M, Lerchner A. Kallen J, et al. Among authors: stiefl n. ChemMedChem. 2018 Sep 19;13(18):1997-2007. doi: 10.1002/cmdc.201800344. Epub 2018 Aug 16. ChemMedChem. 2018. PMID: 29985556
Medicinal Chemistry Aware Database GDBMedChem.
Awale M, Sirockin F, Stiefl N, Reymond JL. Awale M, et al. Among authors: stiefl n. Mol Inform. 2019 Aug;38(8-9):e1900031. doi: 10.1002/minf.201900031. Epub 2019 Jun 6. Mol Inform. 2019. PMID: 31169974
Ten simple rules to power drug discovery with data science.
Ferrero E, Brachat S, Jenkins JL, Marc P, Skewes-Cox P, Altshuler RC, Gubser Keller C, Kauffmann A, Sassaman EK, Laramie JM, Schoeberl B, Borowsky ML, Stiefl N. Ferrero E, et al. Among authors: stiefl n. PLoS Comput Biol. 2020 Aug 27;16(8):e1008126. doi: 10.1371/journal.pcbi.1008126. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32853229 Free PMC article. No abstract available.
Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
Ullrich T, Arista L, Weiler S, Teixeira-Fouchard S, Broennimann V, Stiefl N, Head V, Kramer I, Guth S. Ullrich T, et al. Among authors: stiefl n. Bioorg Med Chem Lett. 2022 May 15;64:128667. doi: 10.1016/j.bmcl.2022.128667. Epub 2022 Mar 8. Bioorg Med Chem Lett. 2022. PMID: 35276359
Evolution of Novartis' Small Molecule Screening Deck Design.
Schuffenhauer A, Schneider N, Hintermann S, Auld D, Blank J, Cotesta S, Engeloch C, Fechner N, Gaul C, Giovannoni J, Jansen J, Joslin J, Krastel P, Lounkine E, Manchester J, Monovich LG, Pelliccioli AP, Schwarze M, Shultz MD, Stiefl N, Baeschlin DK. Schuffenhauer A, et al. Among authors: stiefl n. J Med Chem. 2020 Dec 10;63(23):14425-14447. doi: 10.1021/acs.jmedchem.0c01332. Epub 2020 Nov 3. J Med Chem. 2020. PMID: 33140646 Review.
40 results